Skip to content

The Th17/Treg Cells and IL-23/IL-17 Axis and Early Enteral Nutrition in Sepsis

The Roles of Th17/Treg Cells and IL-23/IL-17 Axis in the Mechanisms of Early Enteral Nutrition Improving Immune Function of Sepsis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03385850
Enrollment
53
Registered
2017-12-29
Start date
2017-10-01
Completion date
2018-12-31
Last updated
2019-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enteral Feeding, Immune System Disorder, Sepsis

Brief summary

The investigators aim to evaluate the roles of Th17/Treg cells and IL-23/IL-17 axis in the mechanisms of early enteral nutrition (EEN) correcting immune imbalance of sepsis by means of improving the intestinal flora disturbance. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis

Interventions

OTHERenteral nutrition

early enteral nutrition group or delayed enteral nutrition group

Sponsors

Nanjing First Hospital, Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of sepsis 2. Within 3 days of sepsis onset before ICU admission 3. No artificial nutrition (enteral or parenteral nutrition) were provided before ICU admission

Exclusion criteria

1. Ileus 2. Digestive tract hemorrhage 3. Inflammatory bowel disease 4. Abdominal hypertension (IAP \>25mmHg) 5. Cancer or chronic organ dysfunction (e.g., hepatic or renal dysfunction) 6. Malnutrition or immunodeficiency 7. Long-term use of hormones

Design outcomes

Primary

MeasureTime frame
28-d mortality28 days

Secondary

MeasureTime frameDescription
immune parameters7 daysserum Th17 and Treg lymphocyte percentages

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026